ASRI Announces Groundbreaking Discovery: Bifunctional 5-HT2A Antagonist And Sodium Channel Blocker Holds Promise For ...
(MENAFN- PR Newswire) LAFAYETTE, Calif., May 31, 2024 /PRNewswire/ -- The Alexander Shulgin Research Institute (ASRI) has unveiled a groundbreaking discovery in the journal Molecular Pharmacology: the first bifunctional compound that acts as both a …